6
Clinical Trials associated with HPV-16 targeted mRNA vaccine(Novi Technology) / Not yet recruitingPhase 1/2 A Phase I/IIa, Randomized, Double Blind, Placebo Controlled, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of NWRD09 Injection in Female Participants With Persistent HPV16 Infection
This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.
/ Not yet recruitingPhase 2 A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD09 in Patients With HPV16-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human papillomavirus (HPV) 16.
An Exploratory Clinical Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region: Safety and Preliminary Efficacy Observation
This is an open-label, single-center, investigator-initiated exploratory trial evaluating NWRD09 in 10 participants with persistent HPV16 infection in the anal region.
100 Clinical Results associated with HPV-16 targeted mRNA vaccine(Novi Technology)
100 Translational Medicine associated with HPV-16 targeted mRNA vaccine(Novi Technology)
100 Patents (Medical) associated with HPV-16 targeted mRNA vaccine(Novi Technology)
100 Deals associated with HPV-16 targeted mRNA vaccine(Novi Technology)